Markman Advisors
Patent Valuation, Monetization and Investments

Blog

Markman Advisors Patent Blog

by Zachary Silbersher

Posts tagged apolipoprotein B
Amarin: Response to comments on Kurabayashi.

We have received several follow-up questions, both online and offline, regarding some of our earlier posts – especially on the topics of Kurabayashi and prospective settlement. This post will attempt to collect further thoughts on Kurabayashi. This post gets deeper into the weeds than most of our earlier posts, but it is in response to thoughtful questions and comments that investors clearly looking for areas of weakness in the district court’s opinion. We will follow up shortly on another post discussing dynamics of a potential settlement.

Read More
Markman AdvisorsAmarin, Amarin Pharmaceuticals, AMRN, $AMRN, EPA, Kurabayashi, patent, DHA, Apo B, Apo-B, apolipoprotein B, Hikma, Dr. Reddy's, Miranda Du, Miranda M. Du, Judge Du, Vascepa Comments
Can Amarin’s patents protect Vascepa from generics?

Amarin Pharmaceuticals ($AMRN) will be going to trial soon to protect Vascepa® against generic competition.  Amarin has asserted 15 claims from six patents against ANDAs filed by Hikma, Dr. Reddy’s and Teva.  What are the issues to be addressed at trial?

Read More
Markman AdvisorsAmarin, Amarin Pharmaceuticals, $AMRN, AMRN, Vascepa, Hikma, Dr. Reddy's, Teva, $TEVA, MARINE, REDUCE-IT, generic, patent, Hatch-Waxman, Nevada, District of Nevada, hypertriglyceridemia, triglycerides, Epadel, Lovasa, LDL-C, EPA, Apo-B, apolipoprotein B, Zachary Silbersher, Silbersher Comments